Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 10/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1432645 | 0.84 | AOC3 (0.56) | AOC3KDM4ELMNANR3C2 | |
| SCHEMBL9381248 | 0.83 | NR3C2 (0.43) | AOC3KDM4ELMNANR3C2MAPK8 | |
| Hydrochloric Acid SCHEMBL1432791 | 0.83 | AOC3 (0.55) | AOC3KDM4ELMNANR3C2 | |
| SCHEMBL27808985 | 0.82 | AOC3 (0.47) | AOC3KDM4ELMNANR3C2MAPK8 | |
| Hydrochloric Acid SCHEMBL27981485 | 0.81 | AOC3 (0.47) | AOC3KDM4ELMNANR3C2MAPK8 | |
| SCHEMBL9376288 | 0.78 | LCK (0.42) | AOC3KDM4ELMNANR3C2MAPK8 | |
| SCHEMBL9376945 | 0.78 | RAB9A (0.49) | LMNAKCNH2ALDH1A1 | |
| SCHEMBL27808982 | 0.77 | NR3C2 (0.39) | AOC3KDM4ELMNANR3C2MAPK8 | |
| SCHEMBL6795355 | 0.77 | AOC3 (0.50) | AOC3NR3C2MAOBGFERHDAC1 | |
| SCHEMBL27697741 | 0.77 | KDM4E (0.57) | KDM4ELMNANR3C2MAPK8NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
| EP-0356234-B1 | New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-05-11 | — | — | EP | disclosed |
| US-5047411-A | Antiulcer Agents, H2-Receptor Antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0356234-A2 | New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | AOC3 274/4885KDM4E 3114/4885LMNA 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.